February 09, 2011

Solid results in 2010

 

Solid results in 2010

Commenting on the Group’s performance in 2010, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, “2010 was the first year in which the patent cliff really became visible with generic competition for several of our products, notably Lovenox® in the U.S. However, we have delivered another year of EPS growth due to the excellent performance of our growth platforms, which now account for 54% of sales, and tight cost control. In 2010, these growth platforms accounted for more than €16 billion in sales, an increase of 12.5%, constituting a solid basis for the mid and long term development of our company.”